Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.
2.

Neovascular age-related macular degeneration: individualizing therapy in the era of anti-angiogenic treatments.

Heier JS.

Ophthalmology. 2013 May;120(5 Suppl):S23-5. doi: 10.1016/j.ophtha.2013.01.059.

PMID:
23642783
3.

Therapeutic anti-VEGF in age-related macular degeneration: Ranibizumab and Bevacizumab controversy.

Moreno SF, Paloma JB.

Br J Ophthalmol. 2008 Jun;92(6):866-7. No abstract available.

PMID:
18523097
4.

[Age-related macular degeneration].

Kernt M, Wolf A, Kampik A.

MMW Fortschr Med. 2013 Feb 7;155(2):43-5; quiz 46-7. Review. German. No abstract available.

PMID:
23573745
5.

Developments in age-related macular degeneration: Diagnosis and treatment.

Kaufman SR.

Geriatrics. 2009 Mar;64(3):16-9. Review.

PMID:
19351219
6.

Influence of ranibizumab on vascular endothelial growth factor plasma level and endothelial progenitor cell mobilization in age-related macular degeneration patients: safety of intravitreal treatment for vascular homeostasis.

Machalińska A, Paczkowska E, Pabin T, Safranow K, Karczewicz D, Machaliński B.

J Ocul Pharmacol Ther. 2011 Oct;27(5):471-5. doi: 10.1089/jop.2011.0091. Epub 2011 Aug 10.

PMID:
21830945
7.

[Intravitreal anti-VEGF injections improve the visual prognosis of wet age related macular degeneration].

Ambresin A, Mantel I.

Rev Med Suisse. 2007 Jan 17;3(94):137-41. Review. French.

PMID:
17354539
8.

Exudative AMD subtypes and eligibility for treatment with ranibizumab.

George S, Cooke C, Chakravarthy U.

Eye (Lond). 2010 Jul;24(7):1247-51. doi: 10.1038/eye.2009.301. Epub 2009 Dec 18.

PMID:
20019764
9.

Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.

Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, Greene WL, Shams N.

Ophthalmology. 2005 Jun;112(6):1048-53.

PMID:
15885778
10.

Age-related macular degeneration.

Noble J, Chaudhary V.

CMAJ. 2010 Nov 9;182(16):1759. doi: 10.1503/cmaj.090378. Epub 2010 Aug 9. Review. No abstract available.

11.

Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.

Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, Wiedemann P, Simader C, Gekkieva M, Weichselberger A; EXCITE Study Group.

Ophthalmology. 2011 May;118(5):831-9. doi: 10.1016/j.ophtha.2010.09.004. Epub 2010 Dec 13.

PMID:
21146229
12.

Refractive error and smoking habits in exudative age-related macular degeneration in a hospital-based setting.

Tao Y, Jonas JB.

Eye (Lond). 2010 Apr;24(4):648-52. doi: 10.1038/eye.2009.160. Epub 2009 Jul 10.

PMID:
19590519
13.

Prospective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a pilot study.

Flaxel C, Schain MB, Hamon SC, Francis PJ.

Retina. 2012 Mar;32(3):417-23. doi: 10.1097/IAE.0b013e318229b0af.

PMID:
21862953
14.

Cystoid macular degeneration in exudative age-related macular degeneration.

Querques G, Coscas F, Forte R, Massamba N, Sterkers M, Souied EH.

Am J Ophthalmol. 2011 Jul;152(1):100-107.e2. doi: 10.1016/j.ajo.2011.01.027. Epub 2011 May 12.

PMID:
21570056
15.

Ranibizumab treatment for neovascular age-related macular degeneration: from randomized trials to clinical practice.

Michalova K, Wickremasinghe SS, Tan TH, Chang A, Harper CA, Downie JA, Hunyor AP, Guymer RH.

Eye (Lond). 2009 Aug;23(8):1633-40. doi: 10.1038/eye.2009.175. Epub 2009 Jul 31.

PMID:
19648888
16.

[Ranibizumab for treatment of exudative age-related macular degeneration--own experience].

Wykrota H, Gierek-Lapińska A, Trzciakowski K, Gajdzik-Gajdecka U.

Klin Oczna. 2007;109(10-12):402-9. Polish.

PMID:
18488382
17.

Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.

Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.

Ophthalmology. 2009 Dec;116(12):2393-9. doi: 10.1016/j.ophtha.2009.05.039. Epub 2009 Oct 7.

PMID:
19815292
18.

Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration.

Smailhodzic D, Muether PS, Chen J, Kwestro A, Zhang AY, Omar A, Van de Ven JP, Keunen JE, Kirchhof B, Hoyng CB, Klevering BJ, Koenekoop RK, Fauser S, den Hollander AI.

Ophthalmology. 2012 Nov;119(11):2304-11. doi: 10.1016/j.ophtha.2012.05.040. Epub 2012 Jul 26.

PMID:
22840423
19.

Acute generalised exanthematous pustulosis following intravitreal Ranibizumab.

Bosanquet DC, Davies WL, May K, Harding KG, Patel GK.

Int Wound J. 2011 Jun;8(3):317-9. doi: 10.1111/j.1742-481X.2011.00799.x. Epub 2011 Apr 12.

PMID:
21486393
20.

Supplemental Content

Support Center